BUHLMANN News

New Health Canada License for BÜHLMANN fCAL® turbo

BÜHLMANN fCAL® turbo Speed, Quality and Flexibility in Calprotectin Quantification BUHLMANN Diagnostics Corp (BDC), BÜHLMANN Laboratories AG’s North American affiliate is proud to announce that its innovative product, BÜHLMANN fCAL® turbo, has received a Medical Device License from Health Canada and is now commercially available in Canada.  The device was approved as a Class 2
Continue Reading

Connect with BUHLMANN Diagnostics Corp (BDC) at DDW 2016

When: May 21-24, 2016 Where: San Diego, California Booth: #4155 More Information: Digestive Disease Week (DDW) 2016
Continue Reading

Calprotectin Video from Canadian Digestive Health Foundation (CDHF)

The Canadian Digestive Health Foundation (CDHF) has recently produced a very interesting video about the use of calprotectin to confirm and predict flares in inflammatory bowel disease patients and how it can be used to manage IBD.

Continue Reading

Connect with BUHLMANN Diagnostics Corp at CDDW 2016

When: February 26 - 29, 2016 Where: Montreal, Quebec, Canada - Fairmont Queen Elizabeth Hotel' Booth: #1050 More Information Canadian Digestive Diseases Week
Continue Reading

Random Access Immuno Turbidimetric Faecal Calprotectin Assay

In autumn 2015 BÜHLMANN will launch a new generation of faecal calprotectin assay. The BÜHLMANN fCAL™turbo, the next step in automation of faecal calprotectin quantification used for Research Use Only. Fecal calprotectin (fCAL) is the most important marker in the study of gut inflammation. fCAL testing today demands for a raised level of lab resources including

Continue Reading

Market Launch Of CALEX Device

  BÜHLMANN announces the launch and introduction of the brand new stool extraction device CALEX® Cap. The features of the CALEX® extraction tool are unique in the market: Ease of use for laboratory personnel and subjects Application as primary tube for all ELISA robots on the market An optimized sample dilution for maximum efficiency in

Continue Reading